T
Takafira Mduluza
Researcher at University of Zimbabwe
Publications - 133
Citations - 3828
Takafira Mduluza is an academic researcher from University of Zimbabwe. The author has contributed to research in topics: Schistosoma haematobium & Schistosomiasis. The author has an hindex of 34, co-authored 115 publications receiving 3380 citations. Previous affiliations of Takafira Mduluza include University of KwaZulu-Natal & College of Health Sciences, Bahrain.
Papers
More filters
Journal ArticleDOI
Association between genital schistosomiasis and HIV in rural Zimbabwean women.
Eyrun Floerecke Kjetland,Patricia D. Ndhlovu,E. Gomo,Takafira Mduluza,Nicholas Midzi,Lovemore Gwanzura,Peter R. Mason,Leiv Sandvik,Henrik Friis,Svein Gunnar Gundersen +9 more
TL;DR: Women with genital schistosomiasis had an almost three-fold risk of having HIV in this rural Zimbabwean community, and HIV prevalence was found in the 25–29 years age group.
Journal ArticleDOI
Simple clinical manifestations of genital schistosoma haematobium infection in rural zimbabwean women
Eyrun Floerecke Kjetland,Patricia D. Ndhlovu,Takafira Mduluza,E. Gomo,Lovemore Gwanzura,Peter R. Mason,Edith Nyaradzai Kurewa,Nicholas Midzi,Henrik Friis,Svein Gunnar Gundersen +9 more
TL;DR: The prevalence of gynecologic S. haematobium infection in the female genitals is described and the presence of ova was not a predictor for ulcers, papillomata, leukoplakia, polyps, or cell atypia.
Journal ArticleDOI
Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection
Francisca Mutapi,Patricia D. Ndhlovu,Paul Hagan,J. T. Spicer,Takafira Mduluza,C. M. R. Turner,S. K. Chandiwana,Mark E. J. Woolhouse +7 more
TL;DR: Treatment of Schistosoma haematobium-infected children with the drug praziquantel induced a switch from a predominantly IgA-specific antibody response to a majority IgG1 response within 12 weeks, which suggests that prazquantel treatment may have an immunizing effect, with benefits extending beyond a transient reduction in levels of infection.
Journal ArticleDOI
Schistosoma haematobium Treatment in 1–5 Year Old Children: Safety and Efficacy of the Antihelminthic Drug Praziquantel
Francisca Mutapi,Nadine Rujeni,Claire D. Bourke,Kate M. Mitchell,Laura J. Appleby,Norman Nausch,Nicholas Midzi,Takafira Mduluza +7 more
TL;DR: PZQ treatment is as safe and efficacious in children aged 1–5 years as it is in older children aged 6–10 years in whom PZQ is the drug of choice for control of schistosome infections.
Journal ArticleDOI
Praziquantel Treatment of Individuals Exposed to Schistosoma haematobium Enhances Serological Recognition of Defined Parasite Antigens
Francisca Mutapi,Richard Burchmore,Takafira Mduluza,Aude Foucher,Yvonne Harcus,Gavin Nicoll,Nicholas Midzi,C. Michael R. Turner,Rick M. Maizels +8 more
TL;DR: This study is the most comprehensive characterization of S. haematobium antigens to date and describes novelantigens in all schistosome species.